Replies to post #158525 on Anavex Life Sciences Corp (AVXL)

[TTTav66]

Maybe not a monster press conference (and I've mentioned this before) but I like the fact that less than 1 week after the AAIC presentations, Dr. Missling will have some good stage time to expand on things with both an endpoints-based panel discussion and a half hour solo presentation covering the genomic analysis and other steps they've taken to increase the likelihood of clinical trial success. Not sure if we—as non-attendees—will hear anything out of this, but good to see the story being told further in the days immediately following AAIC.

July 31: NDD Neuropsychiatric Drug Development Summit - Boston, MA

Panel Discussion: What are the Right Kinds of End Points, Where There Aren’t Any Approved?
Michael Palfreyman - Chief Scientific Officer, Amorsa Therapeutics
Christopher Missling - Chief Executive Officer, Anavex Life Sciences
Eva Kohegyi - Senior Director, Global Clinical Development CNS, Otsuka
Synopsis
• Exploring areas where endpoints haven’t been approved and understanding why this is
• Discussing the benefits and disadvantages of hard and soft endpoints in neuropsychiatry
• Reviewing why certain endpoints haven’t been approved and how to overcome this

Delving into Technology & Enablers, How They can be Used to Enhance & Transform Clinical Trials
Christopher Missling - Chief Executive Officer, Anavex Life Sciences
Synopsis
• Using early on Population PK, i.e. non-linear mixed effect (NLME) modelling an formal concept analysis (FCA)
• Include early on both RNA whole exome and DNA denome sequencing of patients
• Goal is to increase clinical success in pivotal studies

https://www.ndd-summit.com/about/agenda/